-
Mashup Score: 5INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra - 6 day(s) ago
Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial. The study examines the efficacy of nivolumab and ipilimumab combination therapy in molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Mehra discusses the trial’s design, which focuses on four subgroups: mismatch repair deficiency, high tumor mutational burden, CDK12 inactivation, and BRCA2…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor - 6 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A. Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Rana McKay, MD , Medical Oncologist, Associate Professor of…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Case-based discussion on navigating the evolving landscape of castrate-resistant #ProstateCancer management. Oliver Sartor, MD @MayoClinic joins @DrRanaMcKay @UCSanDiego as part of an independent medical education initiative on UroToday > https://t.co/ygi8XDjAQC @BayerPharma https://t.co/OZG83QZgbB
-
-
Mashup Score: 9Traction Therapy Helps Men Regain Penile Length After Prostate Cancer Treatment - Amy Pearlman - 6 day(s) ago
Amy Pearlman discusses penile traction therapy using the RestoreX device, a second-generation technology designed to address penile length changes after prostate cancer treatment. Dr. Pearlman explains how this device, developed by Dr. Landon Trost at Mayo Clinic, offers advantages over first-generation devices through its dynamic stretching capabilities and shorter required usage times. The…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Traction therapy helps men regain penile length after #ProstateCancer treatment. @AmyPearlman1 joins @DrDianeNewman to discuss penile traction therapy using the #RestoreX device #WatchNow on UroToday > https://t.co/8xXfBinwwe @PathRightMed https://t.co/aHeVGo8aVG
-
-
Mashup Score: 15Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett - 7 day(s) ago
Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Phase 3 #CLARIFY trial investigates 64Cu-SAR-bisPSMA PET for improved detection. @drlouiseemmett and @zklaassen_md discuss the diagnostic performance of copper-64 bisPSMA PET-CT in high-risk #PCa patients before radical prostatectomy > https://t.co/hRFvY3NdHE @Clarity_Pharma https://t.co/COhQFTPfAb
-
-
Mashup Score: 4Advances and Challenges in High-Risk CSPC: A Multidisciplinary Approach to Patient Management - Paul Sieber - 7 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Paul Sieber, MD, FACS, Keystone, Urology Specialists, Lancaster, PA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clinics, Chief Medical Officer,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances and challenges in high-risk #CSPC: a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > https://t.co/yx14ySV0XT @BayerPharma https://t.co/3aJQsloW0Q
-
-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 7 day(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The current state of treatment implementation for metastatic hormone-sensitive #ProstateCancer in #NorthAmerica. #LibraryResource @zklaassen_md @GACancerCenter and @RKSayyid @UofT discuss on UroToday > https://t.co/VDtUiLis3m https://t.co/zNuUo8rc9H
-
-
Mashup Score: 13PSMA PET Imaging and Targeted Therapies: A Case Study on High-Risk Localized Prostate Cancer - Tian Zhang - 8 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Tian Zhang, MD, MHS, Associate Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX Elena Castro, MD, PhD, Hospital Universitario 12 de Octubre,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
PSMA PET imaging and targeted therapies: a case study on high-risk localized #ProstateCancer. @TiansterZhang @UTSWNews and @Ecastromarcos discuss in this Independent Medical Education Initiative on UroToday > https://t.co/k242D9ESRr @BayerPharma https://t.co/d7RoO3stOp
-
-
Mashup Score: 20Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer - 8 day(s) ago
Prostate cancer, advanced prostate cancer, novel targets for mHSPC, Metastatic Hormone Sensitive Prostate Cancer (mHSPC), TITAN study, ENZAMET trial, ARCHES trial, CHAARTED trial, Prognostication in Metastatic Hormone Sensitive Prostate Cancer, androgen deprivation therapy (ADT), PARP inhibition, 177Lu-PSMA-617, PTEN, TP53, RB1, CYCLONE-3 trial, UpFrontPSMA21 trial, STAMPEDE study, KEYNOTE-991 trial, PSMAddition trial, PROMETHEAN trial, ArteraAI Prostate Test, apalutamide, enzalutamide, abiraterone, docetaxel, DECIPHER genomic classifier.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Novel targets and treatment developments in metastatic hormone-sensitive #ProstateCancer. @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss on UroToday > https://t.co/ybjGZhUMA6 https://t.co/dqDmHEfMqK
-
-
Mashup Score: 11Novel Treatment Targets in the Metastatic Castrate-Resistant Prostate Cancer Disease Space - 8 day(s) ago
prostate cancer, metastatic castration resistant prostate cancer (mCRPC), Metastatic Castrate-Resistant Prostate Cancer Disease Space, EPI-7386, EPI-7386 plus Enzalutamide, Enzalutamide, RNAseq, CYPIDES trial, Oral bavdegalutamide (ARV-110), PROteolysis Targeting Chimera (PROTAC), CYCLONE 2 (NCT03706365).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Novel treatment targets in the metastatic castrate-resistant #ProstateCancer disease space. @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss emerging, novel therapeutic targets and/or applications of existing agents in the #mCRPC disease space > https://t.co/UqZjsuT8nu https://t.co/8ndr4DMqZC
-
-
Mashup Score: 5Combining Nuclear Medicine and Immunotherapy for Enhanced Cancer Treatment - Chris Behrenbruch - 8 day(s) ago
Oliver Sartor interviews Chris Behrenbruch about radiopharmaceuticals in cancer treatment. Dr. Behrenbruch discusses his passion for nuclear medicine, emphasizing its multidisciplinary nature and potential for patient impact. They explore the complexities of isotope selection, particularly Lutetium-177 and Actinium-225, highlighting the importance of matching isotopes to specific biological…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Combining #NuclearMedicine and immunotherapy for enhanced cancer treatment. Chris Behrenbruch, MD @TelixPharma joins Oliver Sartor, MD @MayoClinic in this discussion about radiopharmaceuticals in cancer treatment. Full video on UroToday > https://t.co/xVTqjLOMa8 https://t.co/qH3Un4c20p
-
#INSPIRE trial investigates immunotherapy for molecularly selected advanced #ProstateCancer. @NivenMehra @radboudumc joins @neerajaiims @huntsmancancer to discuss the efficacy of nivo + ipi combination therapy in molecularly selected patients with #mCRPC > https://t.co/Rd6NEgCfjT https://t.co/mn9CZ5cAHo